We are live on ! Find out more
WM

WS Management Portfolio holdings

AUM $1.13B
1-Year Est. Return 53.44%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+53.44%
3 Year Est. Return
+163.58%
5 Year Est. Return
+226.76%
10 Year Est. Return
+868.14%
AUM
$3.05B
AUM Growth
-$499M
Cap. Flow
-$609M
Cap. Flow %
-19.99%
Top 10 Hldgs %
59.17%
Holding
84
New
9
Increased
7
Reduced
19
Closed
8

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$53.1M
2
CVNA icon
Carvana
CVNA
+$29.9M
3
STLA icon
Stellantis
STLA
+$17.7M
4
HMHC
Houghton Mifflin Harcourt Company
HMHC
+$16.2M
5
BABA icon
Alibaba
BABA
+$15.9M

Sector Composition

Rank Sector Weight
1 Financials 32.43%
2 Technology 12.18%
3 Consumer Discretionary 11.59%
4 Industrials 8.03%
5 Communication Services 6.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
$6.96M 0.23%
+115,000
New +$6.46M
MHK icon
52
Mohawk Industries
MHK
$7.02B
$6.77M 0.22%
38,605
BKI
53
DELISTED
Black Knight, Inc. Common Stock
BKI
$6.55M 0.22%
126,061
BMRN icon
54
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.33M 0.21%
65,300
CVNA icon
55
PUT
Carvana
CVNA
$45.5B
$5.91M 0.19%
+500,000
New +$5.35M
CLW icon
56
Clearwater Paper
CLW
$281M
$5.79M 0.19%
+195,000
New +$5.24M
HA
57
DELISTED
Hawaiian Holdings, Inc.
HA
$5.69M 0.19%
141,859
WVE icon
58
Wave Life Sciences
WVE
$1.15B
$5.6M 0.18%
112,000
CPB icon
59
Campbell Soup
CPB
$6.69B
$5.2M 0.17%
141,850
BLUE
60
DELISTED
bluebird bio
BLUE
$4.91M 0.16%
2,597
XBI icon
61
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$4.79M 0.16%
50,000
-330,000
-87% -$32M
CLLS
62
Cellectis
CLLS
$286M
$4.33M 0.14%
153,559
F icon
63
Ford
F
$58.1B
$4.29M 0.14%
464,310
QURE icon
64
uniQure
QURE
$2.67B
$4.13M 0.14%
113,500
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.67B
$4.13M 0.14%
54,100
BABA icon
66
PUT
Alibaba
BABA
$274B
$4.12M 0.14%
+25,000
New +$4.42M
SGMO
67
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.12M 0.14%
243,000
ADAP
68
DELISTED
Adaptimmune Therapeutics
ADAP
$4.02M 0.13%
296,783
AUD
69
DELISTED
Audacy, Inc.
AUD
$3.93M 0.13%
497,310
+38,122
+8% +$295K
SLDB icon
70
Solid Biosciences
SLDB
$789M
$3.76M 0.12%
5,313
ABEO icon
71
Abeona Therapeutics
ABEO
$351M
$3.56M 0.12%
11,120
ONCE
72
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.46M 0.11%
63,400
NTLA icon
73
Intellia Therapeutics
NTLA
$1.51B
$3.43M 0.11%
120,000
EDIT icon
74
Editas Medicine
EDIT
$416M
$2.76M 0.09%
86,765
CRSP icon
75
CRISPR Therapeutics
CRSP
$4.65B
$2.53M 0.08%
57,000

Similar funds

WS Management's Q3 2018 Portfolio in Review

As of Q3 2018, WS Management held 84 positions worth $3.05B, down 14% from $3.54B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

WS Management withdrew a net $609M in Q3 2018, closing 8 positions and reducing 19 holdings. Its most notable exit was Meta Platforms (Facebook), an estimated $48.2M position sold in full.

By sector, the portfolio is most concentrated in Financials at 32% of assets, up from 28% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, WS Management opened a new position in Stellantis worth $17.5M.

  • WS Management's largest Q3 2018 buy was Stellantis: 1,000,000 shares worth $17.5M.
  • WS Management added most to Tesla in Q3 2018, an estimated $53.1M increase.
  • WS Management's biggest Q3 2018 reduction was Micron Technology, cutting an estimated $125M.
  • WS Management fully exited Meta Platforms (Facebook) in Q3 2018, selling an estimated $48.2M.
  • WS Management's ten largest holdings make up 59% of its $3.05B portfolio in Q3 2018.
  • WS Management opened 9 new positions and closed 8 in Q3 2018.
  • WS Management's portfolio value fell 14% quarter-over-quarter to $3.05B.

Based on WS Management's 13F filing for Q3 2018, filed 13 Nov 2018.